Was going to mention the same thing about researchers

New Post Public Reply Private Reply Replies (1) Message Board
kabonk havasu78 #76680
706
Was going to mention the same thing about researchers thinking it's a good idea to combine anti-PD-1/PD-L1 with CCR5 blockade as complementary / non-overlapping pathways from that paper.

https://onlinelibrary.wiley.com/doi/abs/10.1111/exd.14065

Quote:

Blockade of CCR5 can be combined with anti‐PD‐1/PD‐L1 with or without anti‐CTLA‐4 drugs since it targets a non‐overlapping pathway. The addition of CCR5 blockade could help decrease the dose of PD1 inhibitors and therefore improve the side effect profile, which is a major obstacle to the use of immunotherapy. While anti‐PD‐1/PD‐L1 enables T‐cell anti‐tumor activity, blockade of CCR5 can prevent MDSCs and T‐regs immune modulation and prevent neutrophilic‐mediated inflammation in the tumor microenvironment.


Other authors recognize some overlap:

https://www.sciencedirect.com/science/article...0X19300612

Quote:
Moreover, several lines of evidence suggest that CCR5 and its ligands appear to participate in the canonical immune check point response. The Programmed Cell Death Protein 1 (CD279 and PD-1) and its ligand PD-1 Ligand (PD-L1) signaling pathway are critical players in immune checkpoints. PD-1 signaling plays an important role in tumor evasion from the innate immune system. In addition, tumor-infiltrating lymphocytes (TILs) serve as a biomarker for predicting responses to PD-L1 blockade therapy. Recent evidence supports that tumors responsive to immunotherapy tend to infiltrate with T cells in response to CTLA-4 and PD-1 antagonism; this process is referred to as a “T cell-inflamed” tumor microenvironment (Gajewski, 2015; Ji et al., 2012; Tumeh et al., 2014). CCL5 upregulation was demonstrated in PD-L1-positive melanoma tumors along with IFNγ and several IFNγ-related genes (Ayers et al., 2017; Taube et al., 2015). Tumor burden and a T cell-inflammatory gene expression were independently predictive of the response to the PD-1 antibody pembrolizumab (Cristescu et al., 2018).

It is also important to analyze the role of MDSC. CCR5high MDSC have higher immunosuppressive activity than CCR5low MDSC (Chang, Lin, Kang, et al., 2012), and when disrupted, MDSC trafficking enhances anti-PD1 therapy (Highfill et al., 2014). As described above, CCL5 promotes not only the influx of CD8+ T-cells (Harlin et al., 2009), but also the expression of PD-L1 when associated with increased TILs. Relatedly, the Keynote-028 study demonstrated that the tumors with high PD-L1 and T cell inflammatory gene expression, were associated with a positive outcome from monoclonal antibody therapy (pembrolizumab) (Seto et al., 2019). Collectively, these studies suggest that overlap exists between the CCR5 non-canonical and canonical immune checkpoint pathways.


Here is a similar recent article showing that inflammatory macrophages near tumor cells secrete CCL5, which then stabilizes PD-L1 on tumor cells. Perhaps LL could keep the macrophages away or re-polarize them so they won't secrete CCL5?

https://www.nature.com/articles/s41418-019-0460-0

Quote:
C-C motif chemokine ligand 5 (CCL5), which is secreted by macrophages, inhibited T-cell-mediated killing of HT29 cells and promoted immune escape by stabilizing PD-L1 in vitro and in vivo. Mechanistically, CCL5 resulted in formation of nuclear factor kappa-B p65/STAT3 complexes, which bound to the COP9 signalosome 5 (CSN5) promoter, leading to its upregulation. Moreover, CSN5 modulated the deubiquitination and stability of PD-L1. High expression of CSN5 in CRC was associated with significantly shorter survival.
..
We propose that CCL5 secreted by macrophages induces the upregulation of PD-L1 in cancer cells, which in turn promotes the infiltration of macrophages, forming a positive feedback loop that facilitates immune escape of cancer cells and subsequently the growth of CRC.


So, it looks like CCL5/CCR5 and PD-L1 do interact, and I think the pathways could be complementary. It's also possible that CCR5 blockade alone could do the trick, but we have to run the trials to find out.

and as ohm noted, the recent paper about the PD-L1 pathway and CCR5 in a BAP-1 mutant mouse model of CRC:

https://jitc.bmj.com/content/8/1/e000228

Quote:
Taken together, these results indicated that CCR5 blockade could enhance the ability of the host immune system to eliminate tumor cells.
..
Besides recruiting CCR5+ Tregs, we also found that BAP1-mutant tumor cells generated CCL2, CCL3 and CCL5, which bound to CCR5 on the cell surface and induced PD-L1 expression. This process could be attenuated by CCR5 inhibitors.
..
These results suggested that combining use of PD-1 inhibitor and maraviroc in BAP1-mutant patients with ccRCC is a direction worth exploring in the future.

The present work has some limitations. The specific mechanism that the CCL5-CCR5 axis induces tumor cells to express PD-L1 at high levels needs to be further elucidated. Additionally, the mechanism by which BAP1 mutation leads to increased expression of CCR5 and its ligands remains to be investigated.


So even the authors whose work ohm qouted suggest the pathways could be complementary.

Lots of recent work has shown that immune checkpoint modulation is dependent on the tumor microenvironment, and even somehow the gut immune environment.

Hopefully blockade of CCL5/CCR5 can create a better tumor immune microenvironment where the proper immune system killer T-cells can get in there to eliminate the tumor without being shut down (by T-Regs, CCL5 secreting macrophages, PD-L1, etc...).

Combo trials make sense, and are already ongoing with maraviroc and the BMS CCR2/CCR5 drug.

Another review talking about the trials:

https://www.mdpi.com/2072-6694/12/7/1765/htm

Quote:
Clinical trials with the CCR5 antagonists maraviroc, leronlimab, vicriviroc and BMS-813160 [17] in triple-negative breast cancer, colorectal cancer, Kaposi’s sarcoma, and advanced pancreatic ductal carcinoma are completed, ongoing or recruiting (Table 3). CCR5 antagonists are being tested in combination with the checkpoint inhibitors pembrolizumab and nivolumab, humanized monoclonal anti-PD-1 antibodies that block PD-1 on T cells, preventing their inactivation by PD-L1 expressed by cancer cells, TAMs, and CAFs.


Some results of one such trial from ASCO last year:

https://ascopubs.org/doi/abs/10.1200/JCO.2020...suppl.3010

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 31

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 82

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 68

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
1031 Specialists Takes Tax Deferral to Public TV

Updated Category News Views 100

A tax rule most people ignore is getting a television spotlight. 1031 Specialists says it will appear on All Access with Andy Garcia, an educational series distributed to Public Television stations nationwide, to explain the 1031 exchange and its role in real estate investing. That is a sensible bit of exposure for a niche business built around a topic investors tend to...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 5

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 44

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 70

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading
Sivers Moves Q3 Release to Accommodate U.S. Investors

Updated Category News Views 74

Thanksgiving has a nasty habit of turning perfectly ordinary earnings dates into ghost towns, and Sivers Semiconductors has sensibly stepped around that pothole. The company will publish its third-quarter 2026 interim report on Monday, November 30, rather than Thursday, November 26. That is not a strategy reset, a warning, or some grand corporate mystery. It is a calendar...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 103

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
Africa Tech Festival Puts Trust Ahead of AI Hype Cycle

Updated Category News Views 75

Fifteen thousand people can fill a convention centre, but they cannot magically deliver a package, fund a small business, or repair harm from a bad automated decision. That rather useful dose of reality ran through the final day of Africa Tech Festival 2026 in Cape Town. The 29th edition drew more than 15,000 delegates across three days, and the strongest message was not...

Continue Reading

Top 5 Most Recently Viewed Articles

Infrastructure Dividend Split Corp. Exciting Class A Updates

Updated Category News Views 208

Infrastructure Dividend Split Corp. Class A Distributions Overview Infrastructure Dividend Split Corp. (TSX:IS) is making headlines with its recent announcement regarding the June 2025 distributions for Class A shareholders. This initiative is a significant opportunity for investors who hold shares in the Fund, and it emphasizes the ongoing commitment to providing value...

Continue Reading
Navigating Market Opportunities with Domino's Pizza Insights

Updated Category News Views 239

Understanding Market Sensitivity and Its Impact In today's financial markets, there’s a heightened sensitivity to news, especially when stock valuations are at all-time highs. With major indices like the S&P 500 reaching unprecedented levels, stocks have become reactive to various news headlines, often regardless of their actual implications on the business. This...

Continue Reading
Noble Corporation plc Reports Strong FY 2024 Financial Results

Updated Category News Views 475

Noble Corporation plc Reports Strong FY 2024 Financial Results Noble Corporation plc (NYSE: NE) has recently reported its outstanding results for the fourth quarter and the entire fiscal year of 2024. The company's financials highlight a remarkable return of over $575 million via dividends and share buybacks, marking a significant milestone in its operational success and...

Continue Reading
Revolutionizing Home Financing: Hard Money Lenders Arizona

Updated Category News Views 171

Revolutionizing Home Financing with Innovative Loans Hard Money Lenders Arizona, a renowned name in alternative lending solutions, has reshaped the landscape of bridge loans, making them more accessible to homebuyers. Under the expert guidance of CEO Michael Iuculano, the firm leverages over 23 years of industry expertise, enabling thousands of clients to successfully...

Continue Reading
Triumph Financial Shifts Stock Listing to NYSE for Growth

Updated Category News Views 105

Triumph Financial Moves to New York Stock Exchange Triumph Financial, Inc. (NASDAQ: TFIN) has made a significant decision to enhance its market presence by transferring the listing and trading of its common and preferred stock to the New York Stock Exchange (NYSE). This strategic move is not just about a change of scenery; it's a calculated step towards unlocking greater...

Continue Reading